Hetland Geir, Fagerhol Magne Kristoffer, Wiedmann Markus Karl Hermann, Søraas Arne Vasli Lund, Mirlashari Mohammad Reza, Nissen-Meyer Lise Sofie Haug, Istre Mette Stausland, Holme Pål Andre, Schultz Nina Haagenrud
Department of Immunology and Transfusion Medicine, Oslo University Hospital Ullevål, 0450 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
Vaccines (Basel). 2022 Aug 6;10(8):1267. doi: 10.3390/vaccines10081267.
ChAdOx1 nCoV-19 vaccination has been associated with the rare side effect; vaccine-induced immune thrombotic thrombocytopenia (VITT). The mechanism of thrombosis in VITT is associated with high levels of neutrophil extracellular traps (NETs). The present study examines whether key markers for NETosis, such as H3-NETs and calprotectin, as well as syndecan-1 for endotheliopathy, can be used as prognostic factors to predict the severity of complications associated with ChAdOx1 vaccination. Five patients with VITT, 10 with prolonged symptoms and cutaneous hemorrhages but without VITT, and 15 with only brief and mild symptoms after the vaccination were examined. Levels of H3-NETs and calprotectin in the vaccinated individuals were markedly increased in VITT patients compared to vaccinees with milder vaccination-associated symptoms, and a strong correlation (r ≥ 0.745, p < 0.001) was found with severity of vaccination side effects. Syndecan-1 levels were also positively correlated (r = 0.590, p < 0.001) in vaccinees to side effects after ChAdOx1 nCoV-19 vaccination. We hypothesize that the inflammatory markers NETs and calprotectin may be used as confirmatory tests in diagnosing VITT.
ChAdOx1 nCoV-19疫苗接种与一种罕见的副作用——疫苗诱导的免疫性血栓性血小板减少症(VITT)有关。VITT中血栓形成的机制与高水平的中性粒细胞胞外诱捕网(NETs)有关。本研究探讨NETosis的关键标志物,如H3-NETs和钙卫蛋白,以及内皮病变的标志物syndecan-1,是否可作为预测ChAdOx1疫苗接种相关并发症严重程度的预后因素。研究检查了5例VITT患者、10例有症状延长和皮肤出血但无VITT的患者以及15例接种疫苗后仅有短暂轻微症状的患者。与疫苗接种相关症状较轻的接种者相比,VITT患者接种者体内H3-NETs和钙卫蛋白水平显著升高,且与疫苗接种副作用的严重程度呈强相关性(r≥0.745,p<0.001)。ChAdOx1 nCoV-19疫苗接种后,syndecan-1水平与接种者的副作用也呈正相关(r = 0.590,p<0.001)。我们推测,炎症标志物NETs和钙卫蛋白可作为诊断VITT的确诊试验。